The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $133.45

Today's change+0.82 +0.62%
Updated August 21 4:00 PM EDT. Delayed by at least 15 minutes.
 

Johnson & Johnson

NYSE: JNJ
Last

(U.S.) $133.45

Today's change+0.82 +0.62%
Updated August 21 4:00 PM EDT. Delayed by at least 15 minutes.

Johnson & Johnson crosses above 50-day moving average

Johnson & Johnson closed up Monday by (U.S.)$0.82 or 0.62% to (U.S.)$133.45 and crossing above its 50-day moving average. Over the last five days, shares are unchanged, but are currently 2.65% below its 52-week high. This security has performed in-line with the S&P 500 during the last year.

Key company metrics

  • Open(U.S.) $132.28
  • Previous close(U.S.) $132.63
  • High(U.S.) $133.65
  • Low(U.S.) $132.19
  • Bid / Ask(U.S.) $133.32 / (U.S.) $133.45
  • YTD % change+15.83%
  • Volume4,534,446
  • Average volume (10-day)4,561,171
  • Average volume (1-month)5,062,532
  • Average volume (3-month)5,550,579
  • 52-week range(U.S.) $109.32 to (U.S.) $137.08
  • Beta0.78
  • Trailing P/E22.57×
  • P/E 1 year forward18.47×
  • Forward PEG2.89×
  • Indicated annual dividend(U.S.) $3.36
  • Dividend yield2.52%
  • Trailing EPS(U.S.) $5.91
Updated August 21 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+22.52%

Based on its net profit margin of 22.52%, Johnson & Johnson is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Pharmaceuticals - Diversified
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJul 02, 201707/02/2017Apr 02, 201704/02/2017Jan 01, 201701/01/2017Oct 02, 201610/02/2016
Revenue18,83917,76618,10617,820
Total other revenue--------
Total revenue18,83917,76618,10617,820
Gross profit13,02912,38412,59012,337
Total cost of revenue5,8105,3825,5165,483
Total operating expense14,09112,19113,78212,539
Selling / general / administrative5,2624,7375,3094,772
Research & development2,2862,0652,6402,179
Depreciation / amortization--------
Interest expense (income), net operating227204184192
Unusual expense (income)128161298109
Other operating expenses, total546-260-110-63
Operating income4,7485,5754,3245,281
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax4,7485,5754,3245,281
Income after tax3,8274,4223,8144,272
Income tax, total9211,1535101,009
Net income3,8274,4223,8144,272
Total adjustments to net income--------
Net income before extra. items3,8274,4223,8144,272
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items3,8274,4223,8144,272
Inc. avail. to common incl. extra. items3,8274,4223,8144,272
Diluted net income3,8274,4223,8144,272
Dilution adjustment--------
Diluted weighted average shares2,7422,7552,7662,785
Diluted EPS excluding extraordinary itemsvalue per share1.401.611.381.53
Dividends per sharevalue per share0.840.800.800.80
Diluted normalized EPSvalue per share1.611.651.501.58